Publications
30
Citations
461
Est. group size
—
Recurring co-author estimate
Active years
37
Publishing since 1990
Jyoti Roy's research focuses on developing and testing radiopharmaceutical imaging and therapeutic agents in preclinical cancer models, particularly for prostate cancer and osteosarcoma (bone cancer). Work includes evaluating PET imaging tracers, radioactive-labeled antibodies, and other tools used to track tumors and monitor treatment response in mouse models. The research also extends to toxicity testing methods for newer drug modalities such as antisense oligonucleotides using lab-grown liver tissue models.
Publication output rose to a peak between 2019 and 2021, then slowed considerably from 2022 through 2025, with a slight uptick projected for 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Predicting antisense oligonucleotide-mediated toxicity using three-dimensional liver microtissue models
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Predicting antisense oligonucleotide-mediated toxicity using three-dimensional liver microtissue models
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model
Cancer Biotherapy and Radiopharmaceuticals · 2023
- Abstract A37: Evaluation of eDHFR/iTag PET reporter gene immunogenicity and application in GPC3 CAR T cells
Cancer Immunology Research · 2022
- <i>In Vitro</i> and <i>In Vivo</i> Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
Cancer Biotherapy and Radiopharmaceuticals · 2021
- Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging
Molecular Imaging and Biology · 2021
- Sodium Fluoride-18 and Radium-223 Dichloride Uptake Colocalize in Osteoblastic Mouse Xenograft Tumors
Cancer Biotherapy and Radiopharmaceuticals · 2021
- Evaluation of [18F]FPy-T140 derivative PET imaging agents for CXCR4 in human cancer xenograft mouse models
Nuclear Medicine and Biology · 2021
- Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents
Cancer Biotherapy and Radiopharmaceuticals · 2020
- Comparison of 3,2-HOPO and DFO-based zirconium-89 antibody complex targeting mesothelin
2020
- Sodium Fluoride-18 Uptake Overlaps Radium-223 Dichloride Uptake in Osteoblastic Bone Tumors
Journal of Nuclear Medicine · 2020
- The Distribution Volume of <sup>18</sup> F-Albumin as a Potential Biomarker of Antiangiogenic Treatment Efficacy
Cancer Biotherapy and Radiopharmaceuticals · 2019
- Comparison of [18F]DCFPyL Analogues Targeting Prostate-Specific Membrane Antigen (PSMA) in Human Prostate Cancer Xenograft (PCaX) Mouse Models
2019
- A Study of 219Rn Outgassing and 211Pb Contamination from 223Ra In dry, Liquid, and Murine Tissue Samples
Health Physics · 2019
- Cancer Biotherapy and Radiopharmaceuticals×5
- Oncotarget×3
- Zenodo (CERN European Organization for Nuclear Research)×2
- Science Translational Medicine×1
- Theranostics×1
- Shuang Liu
Medicine · Purdue University West Lafayette
- Qi‐Huang Zheng
Medicine · Indiana University
- George H. Hinkle
Medicine · The Ohio State University
- Enrico Caserta
Medicine · The Ohio State University
- Edward W. Martin
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile